Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains
Health

Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains

Hitching a ride on a natural cellular transporter allows a conserved flu antigen to cross respiratory barriers and trigger long-lasting immunity.

By David Anderson
Published:
Email this Article
Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains
Expression and characterization of prefusion HA Stalk and Stalk-Fc proteins. (A) Schematic of influenza A virus HA protein, including signal peptide (SP), cleavage site (CS), transmembrane domain (TM), and cytoplasmic tail (CT). The graphic shows the fusion of the HA Stalk with the T4 fibritin foldon domain (Fd) and His tag to produce a soluble, prefusion-stabilized HA Stalk protein. Specific mutations, indicated by asterisks, were introduced in the HA Stalk to stabilize the prefusion form. Additionally, a Stalk-Fc/wt protein was generated by fusing Stalk with foldon and mouse Fcγ2a Fc. Mutations were created in the hinge region by replacing 3 cysteines with serine residues and in the Fc region by modifying Glu318, Lys320, and Lys322 to alanine residues to eliminate the C1q binding site. The Stalk-Fc/mut construct was also generated by incorporating HQ/AD (310/311) and HN/AQ (433/434) mutations (indicated by triangles) to disrupt FcRn binding. To ensure proper domain folding, G/S linke Weizhong Li et al. / The Journal of clinical investigation

Delivering a universal influenza vaccine through the nose by hitching a ride on a specialized cellular transporter successfully protected mice against multiple lethal strains of the virus, a study published in The Journal of clinical investigation indicates. Researchers engineered a novel fusion protein that targets the body’s natural molecular shuttle, known as the neonatal Fc receptor, to cross the respiratory lining and trigger powerful, long-lasting immunity in both the upper and lower airways.

How the Nasal Transporter Delivers Universal Vaccine Protection

Standard flu shots are typically injected into muscle or skin, which often fails to generate robust mucosal immunity right where respiratory viruses first attack. To overcome this hurdle, researchers led by scientists at the University of Maryland focused on the neonatal Fc receptor, a cellular gatekeeper normally responsible for transferring protective antibodies across epithelial barriers. By fusing a modified, stabilized hemagglutinin stalk antigen to a monomeric immunoglobulin G fragment, the team created a compound called Stalk-Fc that naturally binds to this receptor.

When administered intranasally to mice, the Stalk-Fc fusion protein efficiently traversed the polarized cells lining the nasal cavities. Control experiments using animals lacking the receptor or given an unmodified stalk protein showed that this transport mechanism is essential. Without the receptor carrying the antigen across the barrier, the vaccine candidate remained trapped on the surface and failed to elicit a meaningful immune response.

Figure 2: FcRn-mediated transport of the HA Stalk-Fc/wt protein across polarized epithelial cells. (A) In vitro transcytosis of the Stalk-Fc/wt across MDCK cell monolayers expressing FcRn and β2m. MDCKFcRn/β2m cells were grown on the apical side of Transwell inserts to become fully polarized. Stalk-Fc (50 μg/mL) or Stalk (27.5 μg/mL) proteins were added to the apical side and incubated at 37°C for 90 min. An ELISA was conducted to measure the amount of protein transported to the basolateral side. The data presented are the mean ± SEM from 9 individual wells per protein across 2 independent assays. Statistical analysis was conducted using Welch’s 1-way ANOVA (with Dunnett’s T3 multiple-comparison test). ****P < 0.0001. (B) Schematic showing the process of making a nose cryosection for the imaging analysis of in vivo transcytosis. (C) In vivo transcytosis of Stalk-Fc/wt proteins across the epithelial cells lining the nasal cavities of mice. Stalk-Fc or Stalk proteins were conjugated with the fluor
FcRn-mediated transport of the HA Stalk-Fc/wt protein across polarized epithelial cells. (A) In vitro transcytosis of the Stalk-Fc/wt across MDCK cell monolayers expressing FcRn and β2m. MDCKFcRn/β2m cells were grown on the apical side of Transwell inserts to become fully polarized. Stalk-Fc (50 μg/mL) or Stalk (27.5 μg/mL) proteins were added to the apical side and incubated at 37°C for 90 min. An ELISA was conducted to measure the amount of protein transported to the basolateral side. The data presented are the mean ± SEM from 9 individual wells per protein across 2 independent assays. Statistical analysis was conducted using Welch’s 1-way ANOVA (with Dunnett’s T3 multiple-comparison test). ****P < 0.0001. (B) Schematic showing the process of making a nose cryosection for the imaging analysis of in vivo transcytosis. (C) In vivo transcytosis of Stalk-Fc/wt proteins across the epithelial cells lining the nasal cavities of mice. Stalk-Fc or Stalk proteins were conjugated with the fluor Credit: Weizhong Li et al. / The Journal of clinical investigation

What Happens When Immunized Mice Face Lethal Influenza Strains

To test how broadly effective the strategy was, the team challenged the vaccinated mice with lethal doses of various group 1 influenza subtypes, including H1N1, rH5N1, and rH6N2, alongside a field strain of H9N2. While untreated control animals experienced severe weight loss of up to 25 percent and high mortality rates, mice receiving the Stalk-Fc treatment showed strong survival rates ranging from 80% to 91%.

Furthermore, analysis of tissue samples taken four days after infection revealed a notable 1.5 to 2.5 log reduction in live virus levels within the nasal turbinates and lungs of the vaccinated group. The treatment also stimulated the production of long-lived plasma cells in the bone marrow, maintaining detectable antibody levels in blood and respiratory secretions for up to 16 months post-immunization.

Understanding the Cellular Mechanisms Behind the Defense

The researchers evaluated the immune mechanisms responsible for the broad protection, identifying several distinct layers of defense. Vaccinated animals developed significant populations of tissue-resident memory T cells in their lungs, which are specialized immune cells that stay put to fight off future infections rapidly. Additional tests confirmed that even when circulating T cells were chemically sequestered, the lung-resident memory cells alone were enough to protect the mice from lethal H5N1 disease.

Figure 3: FcRn-mediated i.n. immunization significantly enhances HA Stalk–specific Ab immune responses. (A) 10 μg of Stalk-Fc, 5.5 μg Stalk (equivalent molar), or PBS in combination with 10 μg of CpG or 5 μg of c-di-GMP in 20 μL was i.n. administered into 7-week-old C57BL/6 or FcRn KO mice (n = 10). Mice were boosted twice at a 3-week interval. Sampling was done at the indicated time points. (B) The levels of Stalk-specific IgG were measured by ELISA. Symbols represent individual mice, and the horizontal lines indicate the mean ± SEM. (C) The broad bindings of the sera from the Stalk-Fc/wt– or PBS-immunized mice were examined by interacting with the HA1, HA2, HA5, HA9, and HA13 proteins from different influenza subtypes in ELISA. (D) The competitive Stalk binding of the sera from the mice immunized with Stalk-Fc/wt or PBS with the Stalk-specific mAbs KB2, 6F12, and FI6V3 was measured by ELISA. (E–G) Cytokine-secreting cells in the spleen. The spot-forming cells (SFCs) secreting IFN-γ (E), TNF-α
FcRn-mediated i.n. immunization significantly enhances HA Stalk–specific Ab immune responses. (A) 10 μg of Stalk-Fc, 5.5 μg Stalk (equivalent molar), or PBS in combination with 10 μg of CpG or 5 μg of c-di-GMP in 20 μL was i.n. administered into 7-week-old C57BL/6 or FcRn KO mice (n = 10). Mice were boosted twice at a 3-week interval. Sampling was done at the indicated time points. (B) The levels of Stalk-specific IgG were measured by ELISA. Symbols represent individual mice, and the horizontal lines indicate the mean ± SEM. (C) The broad bindings of the sera from the Stalk-Fc/wt– or PBS-immunized mice were examined by interacting with the HA1, HA2, HA5, HA9, and HA13 proteins from different influenza subtypes in ELISA. (D) The competitive Stalk binding of the sera from the mice immunized with Stalk-Fc/wt or PBS with the Stalk-specific mAbs KB2, 6F12, and FI6V3 was measured by ELISA. (E–G) Cytokine-secreting cells in the spleen. The spot-forming cells (SFCs) secreting IFN-γ (E), TNF-α Credit: Weizhong Li et al. / The Journal of clinical investigation

Beyond T cells, the immune sera generated by the nasal delivery exhibited strong neutralizing activity and effectively blocked viral membrane fusion. The antibodies also triggered Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity and phagocytosis, which actively clear virus-infected cells and neutralize pathogens across different group 1 strains.

Limitations and Next Steps for Human Application

Despite the strong results against group 1 influenza strains, the current formulation failed to protect against group 2 viruses like H3N2, reflecting structural differences in the stalk domains of different viral groups. The authors note that future vaccine designs will need to incorporate stalk antigens from group 2 and influenza B viruses, potentially combined with matrix protein 2, to create a truly universal multivalent mucosal vaccine suitable for humans.

The research was published in The Journal of clinical investigation on November 16, 2026.

Fact Checked

This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.

Last reviewed on .

Article history

  • Latest version

Reference(s)

  1. Li, Weizhong., et al. “Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice.” Journal of Clinical Investigation, vol. 136, no. 22, November 16, 2026 American Society for Clinical Investigation, doi: 10.1172/JCI203675. <https://doi.org/10.1172/JCI203675>.

Cite this page:

Anderson, David. “Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains.” BioScience. BioScience ISSN 2521-5760, 18 November 2026. <https://www.bioscience.com.pk/en/subject/health/mucosal-vaccination-with-hemagglutinin-stalk-provides-broad-protection-against-influenza-virus-subtypes-in-mice>. Anderson, D. (2026, November 18). “Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains.” BioScience. ISSN 2521-5760. Retrieved November 18, 2026 from https://www.bioscience.com.pk/en/subject/health/mucosal-vaccination-with-hemagglutinin-stalk-provides-broad-protection-against-influenza-virus-subtypes-in-mice Anderson, David. “Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains.” BioScience. ISSN 2521-5760. https://www.bioscience.com.pk/en/subject/health/mucosal-vaccination-with-hemagglutinin-stalk-provides-broad-protection-against-influenza-virus-subtypes-in-mice (accessed November 18, 2026).
End of the article